Celgene invests $100M, gains option to buy Acetylon

07/29/2013 | Boston Globe (tiered subscription model), The

Celgene agreed to invest $100 million in Acetylon Pharmaceuticals in exchange for an exclusive option to purchase the Boston drugmaker at a price from $500 million to $1.1 billion contingent on certain milestones. Acetylon will use some of the funding to further develop ACY-1215, its lead drug candidate for myeloma. Celgene took a $15 million equity stake in Acetylon last year.

View Full Article in:

Boston Globe (tiered subscription model), The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX